Contract Pharma Staff05.13.20
Ori Biotech Ltd, an innovator in cell and gene therapy (CGT) manufacturing, and CellGenix GmbH, a global supplier of raw and ancillary materials for CGT and regenerative medicine, have announced a non-exclusive strategic partnership to achieve closed-system preparation, formulation and addition of CellGenix media and growth factors within CGT manufacturing for users of the Ori platform.
The Ori platform enables therapy developers and contract manufacturers to achieve automated CGT manufacturing in a closed system. Utilizing innovations from both Ori and CellGenix, users of the Ori manufacturing platform can eliminate process bottlenecks and open steps in media and growth factors formulation, preparation and transfers in order to enable higher throughput and reduce costs by reducing or eliminating manual handling steps.
“Ori Biotech is continuing to build partnerships with best-in-class experts across the cell and gene therapy ecosystem to help enable our provision of integrated, closed system manufacturing to the CGT industry,” said Farlan Veraitch, co-founder and CSO, Ori Biotech. “Innovation around the integration of high quality raw and ancillary materials from CellGenix into the Ori full-stack platform is another step toward enabling our customers to have a fully-closed manufacturing process from end-to-end with no bottlenecks in formulation, preparation and process flow.”
With over 25 years of experience CellGenix are experts in GMP manufacturing of raw materials for the CGT space. CellGenix GMP raw materials offer a maximum of quality and safety.
Till Puschmann, VP R&D and business development, CellGenix added; “Through this collaboration our companies will be able to offer our customers an innovative closed-system manufacturing platform including the necessary high quality raw materials.”
“Through our ecosystem partnerships, we hope to provide our customers with integrated solutions that take some of the hassles out of their supply chain and manufacturing processes to allow them to focus on what they do best, delivering life-saving treatments to the patients who need them,” added Jason C. Foster, CEO, Ori Biotech.
The Ori platform enables therapy developers and contract manufacturers to achieve automated CGT manufacturing in a closed system. Utilizing innovations from both Ori and CellGenix, users of the Ori manufacturing platform can eliminate process bottlenecks and open steps in media and growth factors formulation, preparation and transfers in order to enable higher throughput and reduce costs by reducing or eliminating manual handling steps.
“Ori Biotech is continuing to build partnerships with best-in-class experts across the cell and gene therapy ecosystem to help enable our provision of integrated, closed system manufacturing to the CGT industry,” said Farlan Veraitch, co-founder and CSO, Ori Biotech. “Innovation around the integration of high quality raw and ancillary materials from CellGenix into the Ori full-stack platform is another step toward enabling our customers to have a fully-closed manufacturing process from end-to-end with no bottlenecks in formulation, preparation and process flow.”
With over 25 years of experience CellGenix are experts in GMP manufacturing of raw materials for the CGT space. CellGenix GMP raw materials offer a maximum of quality and safety.
Till Puschmann, VP R&D and business development, CellGenix added; “Through this collaboration our companies will be able to offer our customers an innovative closed-system manufacturing platform including the necessary high quality raw materials.”
“Through our ecosystem partnerships, we hope to provide our customers with integrated solutions that take some of the hassles out of their supply chain and manufacturing processes to allow them to focus on what they do best, delivering life-saving treatments to the patients who need them,” added Jason C. Foster, CEO, Ori Biotech.
